VCYT (Veracyte, Inc.) Stock Financials & Earnings | Market Cap Arena

VCYT (Veracyte, Inc.) Stock Financials & Earnings | Market Cap Arena

VCYTVeracyte, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$517M

Net Income (TTM)$66M

EPS (TTM)$0.82

Free Cash Flow (TTM)$126M

Gross Margin70.6%

Op. Margin9.0%

Net Margin12.8%

FCF Margin24.4%

P/S Ratio (TTM)5.2x

P/E Ratio (TTM)40.2x

YoY Rev Growth+16.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$82M	$56M	-$10M
Q2 23	$90M	$56M	-$8M
Q3 23	$90M	$62M	-$32M
Q4 23	$98M	$69M	-$36M
Q1 24	$97M	$62M	-$5M
Q2 24	$114M	$78M	$5M
Q3 24	$116M	$79M	$12M
Q4 24	$119M	$79M	$4M
Q1 25	$114M	$80M	$3M
Q2 25	$130M	$90M	-$5M
Q3 25	$132M	$91M	$23M
Q4 25	$141M	$105M	$26M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	8.6x	—
Q2 23	8.1x	—
Q3 23	7.8x	—
Q4 23	7.4x	—
Q1 24	7.1x	—
Q2 24	6.7x	—
Q3 24	6.3x	—
Q4 24	6.0x	110.6x
Q1 25	5.8x	80.8x
Q2 25	5.6x	101.4x
Q3 25	5.4x	88.1x
Q4 25	5.2x	40.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$2M	-$3M
Q2 23	$17M	$13M
Q3 23	$14M	$11M
Q4 23	$16M	$13M
Q1 24	-$9M	-$11M
Q2 24	$30M	$27M
Q3 24	$30M	$28M
Q4 24	$25M	$20M
Q1 25	$5M	$4M
Q2 25	$34M	$32M
Q3 25	$45M	$42M
Q4 25	$53M	$48M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$993K
Q2 23	$4M
Q3 23	$3M
Q4 23	$2M
Q1 24	$2M
Q2 24	$3M
Q3 24	$2M
Q4 24	$4M
Q1 25	$2M
Q2 25	$1M
Q3 25	$3M
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+21.6%	+11.9%
Q2 23	+24.0%	+17.7%
Q3 23	+19.2%	+42.9%
Q4 23	+22.3%	+56.0%
Q1 24	+17.5%	+9.2%
Q2 24	+26.7%	+11.6%
Q3 24	+28.6%	-14.8%
Q4 24	+20.8%	-14.4%
Q1 25	+18.2%	+9.9%
Q2 25	+13.8%	+23.3%
Q3 25	+13.8%	+4.9%
Q4 25	+18.5%	+0.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$8M	9.7%
Q2 23	$10M	11.5%
Q3 23	$7M	8.1%
Q4 23	$8M	7.6%
Q1 24	$8M	8.3%
Q2 24	$10M	8.6%
Q3 24	$9M	7.5%
Q4 24	$10M	8.1%
Q1 25	$11M	9.6%
Q2 25	$11M	8.4%
Q3 25	$11M	8.2%
Q4 25	$11M	7.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$13M	$40M	$6M
Q2 23	$13M	$43M	$7M
Q3 23	$13M	$16M	$24M
Q4 23	$19M	$41M	$7M
Q1 24	$16M	$43M	$6M
Q2 24	$16M	$47M	$7M
Q3 24	$18M	$40M	$7M
Q4 24	$19M	$47M	$8M
Q1 25	$18M	$52M	$7M
Q2 25	$16M	$14M	$43M
Q3 25	$16M	$43M	$7M
Q4 25	$21M	$1M	$43M

Revenue Segments

Quarter	Biopharmaceutical And Other	Product	Testing
Q1 23	$6M	$4M	$72M
Q2 23	$5M	$4M	$82M
Q3 23	$4M	$4M	$82M
Q4 23	$4M	$4M	$90M
Q1 24	$3M	$4M	$90M
Q2 24	$4M	$4M	$107M
Q3 24	$3M	$3M	$110M
Q1 25	$4M	$4M	$107M
Q2 25	$4M	$4M	$122M
Q3 25	$1M	$3M	$128M
Q4 25	$686K	$4M	$136M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$178M	$0	$178M
Q2 23	$191M	$0	$191M
Q3 23	$202M	$0	$202M
Q4 23	$216M	$0	$216M
Q1 24	$209M	$0	$209M
Q2 24	$236M	$0	$236M
Q3 24	$274M	$0	$274M
Q4 24	$239M	$50M	$289M
Q1 25	$186M	$101M	$287M
Q2 25	$219M	$101M	$321M
Q3 25	$316M	$51M	$366M
Q4 25	$363M	$50M	$413M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	72M	+0.5%
Q2 23	72M	+0.4%
Q3 23	73M	+0.4%
Q4 23	73M	+0.4%
Q1 24	75M	+2.3%
Q2 24	77M	+3.2%
Q3 24	78M	+1.7%
Q4 24	80M	+1.8%
Q1 25	80M	+0.2%
Q2 25	80M	-0.2%
Q3 25	80M	-0.3%
Q4 25	81M	+2.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$229K	167
FY 15	$258K	192
FY 16	$301K	216
FY 17	$292K	246
FY 18	$341K	270
FY 19	$340K	354
FY 20	$367K	320
FY 21	$288K	761
FY 22	$377K	787
FY 23	$443K	815
FY 24	$541K	824
FY 25	$796	650K